Management of STEC Gastroenteritis: Is There a Role for Probiotics?

Mario Giordano,Maria Elisabetta Baldassarre,Viviana Palmieri,Diletta D. Torres,Vincenza Carbone,Luisa Santangelo,Federico Gentile,Raffaella Panza,Federica Di Mauro,Manuela Capozza,Antonio Di Mauro,Nicola Laforgia
DOI: https://doi.org/10.3390/ijerph16091649
IF: 4.614
2019-05-12
International Journal of Environmental Research and Public Health
Abstract:Shiga toxin-producing Escherichia Coli (STEC) infections routinely run as a common gastroenteritis, but in many cases they may evolve towards hemolytic uremic syndrome (HUS). HUS is a rare disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. Gut microorganisms have a fundamental impact on human physiology, because they modulate normal intestinal functions and play a pivotal role in influencing the local and systemic immune responses. Despite surveillance established in many countries and major progresses in the understanding of STEC-HUS mechanisms, no specific treatment is currently available. Targeting the gut microbiota could represent a new potential therapeutic strategy in STEC infection. In this paper, we reviewed the current knowledge about microbiota characteristics of patients with STEC infections, as well as in vitro and in vivo evidence of probiotic supplementation in managing STEC gastroenteritis and in HUS onset prevention.
public, environmental & occupational health,environmental sciences
What problem does this paper attempt to address?